EC Number   |
Application |
Reference |
|---|
    1.1.1.184 | diagnostics |
expression of CBR mRNA is a significant prognostic factor in nonsmall-cell lung cancer and is inversely associated with tumor progression and angiogenesis |
668135 |
| 1.1.1.184 | drug development |
CBR1 inhibition can improve the therapeutic response to doxorubicin and reduce its side effects |
697582 |
| 1.1.1.184 | drug development |
the cardioprotectant 7-monohydroxyethylrutoside inhibits CBR1 activity. CBR1 V88I genotype status and the type of anthracycline substrate dictate the inhibition of CBR1 activity. Inhibition of CBR1 activity shall be considered during the development of novel cardioprotectants against anthracycline-related cardiotoxicity |
700598 |
| 1.1.1.184 | food industry |
mequindox, inhibitor of several Gram-positive and Gram-negative bacteria, is reduced by carbonyl reductase CBR1 |
724831 |
| 1.1.1.184 | industry |
enzyme has a promising future for industrial application |
696909 |
| 1.1.1.184 | industry |
improved (R)-1-phenyl-1,2-ethanediol production by a codon optimized R-specific carbonyl reductase whose coding gene rcr is engineered by truncating its disorder sequence of 4-27 bp at 5'-terminus and adaption of codon usage bias in Escherichia coli. It will provide a new method to establish an effective expression system for improving chiral alcohol productivity by codon optimization |
695711 |
| 1.1.1.184 | industry |
modification of coenzyme specificity and alteration of product enantioselectivity in SDRs by using the protein engineering approach, which will have valuable industrial applications |
695766 |
| 1.1.1.184 | medicine |
antidepressant bupropion is reduced to erythrohydrobupropion and threohydrobupropion in liver. Menadione and 18beta-glycyrrhetinic acid are inhibitory |
726540 |
| 1.1.1.184 | medicine |
the single nucleotide polymorphisms in the human CBR1 gene generating the V88I and P131S mutations may prove to be clinically useful genetic biomarkers for guiding anthracycline therapy in cancer patients to minimize adverse effects |
697584 |
| 1.1.1.184 | synthesis |
coexpression with glucose dehydrogenase from Bacillus subtilis for NADPH regeneration in Escherichia coli and optimization of linker peptides used for the fusion expression of carbonyl reductase and glucose dehydrogenase. Up to 297.3 g/L (R)-[3,5-bis(trifluoromethyl)phenyl] ethanol with enantiopurity >99.9% ee is produced via reduction of 1.2 M of substrate with a 96.7% yield and productivity of 29.7 g/(L h) |
740965 |
